On August 4, 2023, the Office of Prescription Drug Promotion (OPDP), a branch of the Food and Drug Administration (FDA), took a noteworthy step by issuing a Warning Letter to pharmaceutical giant AstraZeneca. The letter illustrated that statements made by the company in a promotional sales aid regarding the efficacy of its product, BREZTRI AEROSPHERE™ (“Breztri”), were misleading, according to the FDA. This claim is significant since the OPDP has not issued a warning letter for almost a year and a half, with the previous one dating back to February 2022.
The FDA’s move sends a stark reminder of the vital importance of context when presenting claims about a drug’s effectiveness. Misrepresentations can result in considerable consequences, as the AstraZeneca instance exemplifies.
The circumstances surrounding this warning have implications for the industry as a whole, demonstrating the FDA’s stringent standards and its insistence on accurate and precise information when promoting medication to the public. By taking significant actions like a Warning Letter, the FDA ensures the pharmaceutical industry remains aware of its commitment to truthfulness, particularly when it comes to the effectiveness of products.
For a closer look at the specifics of this situation, the original article authored by Sheppard Mullin Richter & Hampton LLP provides a deeper analysis of the issue and its implications.